FINWIRES · TerminalLIVE
FINWIRES

調査速報:カナディアン・パシフィック社、第1四半期の業績が予想を上回り、2026年の業績見通しを改めて発表

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。CPは第1四半期の調整後EPSが1.04ドルとなり、市場予想を0.26ドル上回りました。総収益は、RTM(輸送可能期間)が2%増加したにもかかわらず、2%減の37億ドルとなりました。これは、価格圧力によりRTM当たりの貨物収入が4%減少したためです。営業利益は4%減の13億ドルとなり、営業利益率は70ベーシスポイント上昇して66.0%となりました。これは、KCS統合に伴う継続的なコスト、特に9,100万ドルの買収会計償却費を反映したものです。同社の2万マイルに及ぶ大陸横断ネットワークは、広範な経済情勢による短期的な輸送量制約にもかかわらず、競争上の優位性を維持しています。運行面では、CPはネットワークの円滑性を向上させました。平均列車速度は4%上昇して時速19.9マイル、ターミナル停車時間は8%改善して9.5時間、機関車の生産性は5%向上しました。事業部門別の業績はまちまちだった。穀物部門の売上高はカナダの堅調な生産を背景に11%増の8億7100万ドルとなった一方、産業部門は市場の低迷を反映した逆風に直面した。エネルギー、化学、プラスチック部門は8%減の7億ドル、石炭部門は12%減の2億2600万ドルとなった。

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ